Dr. Richard on the Evolving Armamentarium in Multiple Myeloma


In Partnership With:

Shambavi Richard, MD, highlights the rapidly evolving armamentarium ​in multiple myeloma.

Shambavi Richard, MD, assistant professor of medicine, hematology, and medical oncology, Center of Excellence for Multiple Myeloma, Mount Sinai Hospital, highlights the rapidly evolving armamentarium ​in multiple myeloma.

Historically, treatment options in multiple myeloma elicited suboptimal responses for patients, explains Richard. However, with research focused on deepening and sustaining remissions, the field appears to be entering a new era of improved patient management.

Moreover, in recent years, minimal residual disease ​(MRD) has become a critical end point in several clinical trials, Richard says. ​Now, ​MRD is starting to establish a role in clinical practice.

With the approval of multiple novel therapies, the field ​continues to evolve with the hope of cure in the not-too-distant future, Richard concludes. 

Related Videos
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD
Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center